细胞因子释放综合征中的可药物靶点。
Druggable targets in cytokine release syndromes.
发表日期：2023 Sep 01
作者：
Carlos Luri-Rey, Iñaki Eguren-Santamaria, Ignacio Matos, Pedro Berraondo, Ignacio Melero
来源：
CYTOKINE & GROWTH FACTOR REVIEWS
摘要：
双特异性T细胞诱导剂和CAR T细胞治疗中存在诱发急性全身性炎症反应（细胞因子释放综合征，CRS）的问题。了解可使用临床可用药物中能够中和细胞因子的顺序性波动对于预防或治疗该病症，同时又不危及抗肿瘤治疗的效果至关重要。
Bispecific T-cell engagers and CAR T-cells share the problem of eliciting acute systemic inflammation episodes known as Cytokine Release Syndrome (CRS). Knowledge on the sequential waves of cytokines that can be neutralized with clinically available agents is crucial to prevent or treat this condition without jeopardizing the antitumor therapeutic outcome.